Objective: To investigate the barrier membrane fixation performance and enhanced guided bone regeneration (GBR) capability of a thermosensitive adhesive containing bioactive glass nanoparticles in order to provide a novel solution for membrane fixation during GBR procedures. Methods: M2NP@BGN (methoxyethyl acrylate-co-N-isopropylacrylamide-co-protocatechuic acid@Bioactive glass nanoparticle), a thermosensitive adhesive, was synthesized via free radical polymerization by compositing methoxyethyl acrylate, N-isopropylacrylamide, and protocatechuic acid into a basic adhesive that was modified with bioactive glass nanoparticle (BGN). The successful fabrication of basic adhesive M2NP was characterized by attenuated total reflection-Fourier transform infrared spectroscopy and nuclear magnetic resonance spectroscopy. The thermosensitive adhesive M2NP@BGN (BGN concentration of 1 mg/mL) was characterized by scanning electron microscopy and a rheometer. By adjusting the BGN concentration (0.1 mg/mL, 0.5 mg/mL, 1 mg/mL, and 2 mg/mL), the adhesive and mechanical strengths were investigated with a universal testing machine. Biocompatibility was evaluated with a cell counting kit-8 assay and hemolysis test to identify the optimal formulation. The optimal material’s extract was co-cultured with mouse bone marrow mesenchymal stem cells, and its osteogenic activity was examined in vitro by quantitative real-time PCR, alkaline phosphatase, and alizarin red S staining. The rat mandibular defect model was established, filled with bone graft, and divided into 3 groups based on membrane fixation method: M2NP@BGN (BGN concentration of 1 mg/mL) fixation group (M2NP@BGN), titanium nail fixation group (Nail), and unfixed control group (Negative). Bone regeneration was analyzed after 8 weeks by micro computed tomography and histological staining. Results: M2NP@BGN (BGN concentration of 1 mg/mL) was successfully synthesized and demonstrated rapid gelation under warm, humid conditions. The adhesive with a BGN concentration of 1 mg/mL exhibited the highest adhesive strength (P < 0.001) and significantly enhanced mechanical strength (P < 0.001) under 37℃ wet conditions. All formulations showed excellent biocompatibility, with cell viability > 80% and hemolysis ratio < 5%. M2NP@BGN (BGN concentration of 1 mg/mL) significantly upregulated the expression of Runx2 and Col I (P < 0.001) and enhanced the activity of osteogenic differentiation markers (P < 0.05). In the animal model, the M2NP@BGN group (BGN concentration of 1 mg/mL) achieved significantly higher bone volume fraction and better bone maturity compared to the negative and nail groups (P < 0.05). Conclusion M2NP@BGN (BGN concentration of 1 mg/mL) combines excellent wet adhesion with potent osteogenic activity, enhances the bone augmentation efficacy of membranes, and presents a novel fixation strategy with significant clinical translation potential for GBR therapy.

OBJECTIVE： To investigate the situation and existing problems of the naming of commercially available Chinese patent medicine （CPM） in China， and to put forward the improvement suggestions. METHODS： Announced in Dec. 31， 2017 by CFDA， there were totally 169 601 kinds of national coded drugs. Total of 35 513 kinds of CPM with drug approval number “Z” and 68 kinds of imported CPM with importing registration certificates “Z” was screened by using Excel 2013 software. Based on Naming Technical Guidelines for Generic Name of Chinese Patent Medicines （hereinafter referred to as the Guidelines）， the unqualified situation of domestic CPM were summarized， and unqualified domestic Chinese patent medicine were analyzed statistically in respects of dosage form， special population medication and area. RESULTS： There were 5 091 kinds of drugs named nonconformity with the “Guidelines”， accounting for 14.34％ of domestic CPM. The problems of naming mainly focused on exaggerated naming （1 723 kinds， 33.84％）， dosage form un-located after naming （1 118 kinds， 21.96％）， naming by endangered protected animals and plants （851 kinds， 16.72％）， naming by pharmacology and other related terms （848 kinds， 16.66％）. Names emboding “traditional cultural features” （1 324 kinds， 4.35％） took the lower proportion. Top 5 dosage forms of domestic CPM with unqualified naming were tablets （1 203 kinds， 23.63％）， capsules （821 kinds， 16.13％）， mixture （802 kinds， 15.75％）， pills （706 kinds， 13.87％）， granules （448 kinds， 8.80％）. The problems of special population medication for domestic CPM with unqualified naming concentrated on children’s medication （608 kinds， 11.94％）. The main manufacturers of domestic CPM with unqualified naming came from Guangdong （613 kinds， 12.04％）， Guangxi Zhuang Autonomous Region （371 kinds， 7.29％）， Jilin （265 kinds， 5.21％）， Shaanxi （245 kinds， 4.81％） and Beijing （233 kinds， 4.58％）. CONCLUSIONS： There are many problems in naming of commercially available domestic CPM in China， mainly reflecting as naming type， dosage form， pediatric drugs， etc. There are fewer names emboding “traditional cultural features”. It is suggested that we should further standardize the naming of CPM by strengthening and perfecting the management and examination system of CPM， highlighting the naming principles of Chinese traditional culture and protecting traditional classical brands.

BACKGROUNDFUS2 gene locating at 3p21.3 is considered a promising candidate tumor suppressor gene. The aim of this study is to examine the difference in FUS2-767A/T polymorphism site between lung cancer patients and normal controls in Chinese population.

METHODSThe genotype FUS2-767A/T was detected in 146 lung cancer patients and 113 normal controls by PCR-SSCP method. The relationship between lung cancer risk and difference in genotypes of FUS2 gene was analysed.

RESULTSFUS2-767A/T was significantly related to histological type (P=0.044), age of the patients with lung cancer (P=0.011) and vessel cancer embolus (P=0.031) in lung cancer group. There was no significant difference in distribution of FUS2 genotypes between lung cancer patients and normal controls (P=0.945).

CONCLUSIONSThe results suggest that the FUS2-767A/T polymorphism may be a susceptibility factor for lung cancer among Chinese population.